 The South African Health Products Regulatory Authority SAHPRA has approved the Phase 23 study of once-daily orally-administered RHB-107 upamostat for patients with symptomatic COVID-19 who do not require hospital care Number of U.S. sites for the study has also been expanded RHB-107, a novel antiviral serine protease inhibitor targeting human cell factors, is expected to be effective against emerging viral variants RHB-107 is being developed as a potential treatment with a simple once-daily oral pill in the early course of COVID-19 In parallel RedHills leading oral COVID-19 therapeutic, opaganib, is being evaluated in a global Phase 23 study in 475 patients hospitalized with severe COVID-19, with top-line results upcoming TEL AVIV, Israel and RALEIGH, N.C., Sept. 13, 2021 PRNewswire -- RedHill Biopharma Ltd. 